Daiichi Sankyo Company, Limited announced that a supplemental application for the antiplatelet agent, prasugrel hydrochloride, was filed in Japan to expand the indication for prevention of recurrence of ischemic stroke as a partial change in items of the pharmaceutical manufacturing and marketing approval for prasugrel.